SPS 2017 Program SPS 2017 Program - Page 32

Conclusion: The MTM telepharmacist and nurse played integral roles in facilitating and streamlining focused follow-up appointments between the patient and provider to promptly resolve patient concerns and therapeutic issues. Interprofessional collaboration between the pharmacists and outpatient providers resulted in identification of recommendations regarding: treatment guidelines, dosage adjustments, monitoring parameters, and drug/disease-drug interactions. Future research is needed to determine the impact of longer-term transitional care programs on the number of telepharmacist interventions made and subsequent provider acceptance rates. 5. Interprofessional Medication Therapy Management Services via Collaborative Video Conferencing Technology for Patients with Epilepsy Kate Johnson, BSN, RN, Jennifer Bingham, PharmD, David Rhys Axon, MPharm, Sandra Leal, PharmD, MPH SinfoníaRx, University of Arizona Medication Management Center Background: Patients with epilepsy often face challenges with access to healthcare and management of their conditions. 1) Additionally, patients living in rural areas typically have poorer access to clinical pharmacy services than their urban counterparts. 2) Limited literature exists regarding interprofessional collaboration via video conferencing for these patients. Methods: A University of Arizona Medication Management Center (UAMMC) clinical telepharmacist participated in weekly, collaborative video conferencing appointments between Epilepsy Foundation patients and their epileptologist. During the consultation, the UAMMC telepharmacist: performed a comprehensive medication review (CMR); evaluated the patient’s medication list for safety concerns and medicationrelated problems (MRPs); provided patient counseling; and collaborated with the epileptologist on clinical decision making (e.g., dosing, side effects, and pharmacy-related questions). Each patient received a typewritten medication list and personalized action plan via mail, following his/her appointment. Patients received a follow-up phone call from the UAMMC telepharmacist three to six months after the initial review, depending on the severity of concerns identified initially. The telepharmacist documented notes and medicationrelated recommendations in the Epilepsy Foundation’s electronic health record following all consultations. Results: Initial CMRs were completed with 63 patients resulting in identification of: 66 drug-drug interactions; 37 adverse drug reactions; 35 dose-related safety concerns; 13 therapeutic duplications; and 13 drug-disease interactions. Patients had an average of 2.60 (SD: 2.14) MRPs identified per person. Roughly one fifth (17.5%) of patients self-reported “sometimes”, “often”, or “very often” forgetting to take their medications in the past month, prompting additional telepharmacist-delivered adherence counseling. Conclusions: Preliminary analysis revealed positive program outcomes, suggesting that this telehealth program offers a novel and feasible solution for integrating clinical pharmacists into standard epilepsy care and increasing respective rural patients’ access to MTM services. Future research is needed to examine the cost effectiveness of this type of collaboration and explore patient-related outcomes in diverse populations and clinical settings. 6. What Makes an Effective User Interface for Virtual Care Solutions? Scott Brown and Kevin L. Smith, DNP, FNP, FAANP Zipnosis, Inc. Background: Innovative care delivery through virtual care holds enormous potential for driving care quality and efficiency, customizing support for patients, and promoting patient engagement to produce positive health outcomes. However, before virtual care can achieve its potential, patients need to embrace it. User experience (UX) plays a key role in driving adoption of digital health technologies like virtual care. In fact, adoption and sustained use of technology are tied directly to ease of use and the perceived utility of available information. Methods: Zipnosis partnered with a user experience consulting firm to perform a comprehensive UX research project. This project consisted of 1:1 interviews during which users worked through a series of tasks in the application. Qualitative and quantitative data was collected to evaluate the user experience both before and after redesign. Results: The interviews uncovered several important areas UX needs to address: Ease of use—the process for accessing care needs to be simple and intuitive for patients accessing care. Expectations—patients want to know what to expect regarding process, payment, and possible outcomes prior to starting a visit. Generational preferences —different age groups preferred to interact with virtual care differently, and needed varying levels of assistance throughout the process. Empathy—patients were seeking empathetic language in digital interactions, just as they would in an in-person interaction with a healthcare provider. Conclusions: Post-redesign interviews indicate that a usercentered design in virtual care can improve patient satisfaction. The redesigned platform is moving into pilot phase with several health systems. Anticipated results, based on UX interventions in a variety of industries and software products, include improved adoption, reduced visit abandonment, 32 | Page Conclusion: The MTM telepharmacist and nurse played inte- gral roles in facilitating and streamlining focused follow-up appointments between the patient and provider to promptly resolve patient concerns and therapeutic issues. Interprofes- sional collaboration between the pharmacists and outpatient providers resulted in identification of recommendations re- garding: treatment guidelines, dosage adjustments, monitor- ing parameters, and drug/disease-drug interactions. Future research is needed to determine the impact of longer-term transitional care programs on the number of telepharmacist interventions made and subsequent provider acceptance rates. 5. Interprofessional Medication Therapy Management Services via Collaborative Video Conferencing Technology for Patients with Epilepsy Kate Johnson, BSN, RN, Jennifer Bingham, PharmD, David Rhys Axon, MPharm, Sandra Leal, PharmD, MPH SinfoníaRx, University of Arizona Medication Management Center Background: Patients with epilepsy often face challenges with access to healthcare and management of their condi- tions. 1) Additionally, patients living in rural areas typically have poorer access to clinical pharmacy services than their urban counterparts. 2) Limited literature exists regarding in- terprofessiona Ʌѥ٥٥ɕȁѡ͔)ѥ̸)5ѡUٕͥ䁽ɥ齹5ѥ5) ѕȀU55 ѕɵЁѥѕݕ)䰁Ʌѥٔ٥ɕѵ́ݕ)չѥѥ́ѡȁѽиɥ)ѡձхѥѡU55 ѕɵəɵ)ɕͥٔѥɕ٥܀ 5H쁕مՅѕѡ)ѥӊéѥЁȁͅ䁍ɹ́ѥ)ɕѕɽ̀5IA̤ɽ٥ѥЁչ͕쁅)ɅѕݥѠѡѽЁͥ)̰ͥͥɵɕѕՕ̴)ѥ̤ѥЁɕٕɥѕѥЁ)ͽ镐ѥ٥ݥ̽ȁд)иAѥ́ɕٕܵɽѡ)U55 ѕɵЁѡɕѼͥѡ́ѕȁѡѥ)ɕ٥ܰѡ͕ٕɥ䁽ɹ́ѥ)ѥ丁QѕɵЁյѕѕ́ѥ)ɕѕɕѥ́ѡչѥé)ɽѠɕɐݥձхѥ̸)Iձ%ѥ 5ÍݕɔѕݥѠ́ѥ́ɔ)ձѥѥѥ؁՜՜ѕɅѥ)ٕ͔՜ɕѥԁ͔ɕѕͅ䁍ɹ)ѡɅѥѥ쁅́՜͕͔ѕɅѥ̸)Aѥٕ́ɅȸMȸФ5IÁѥ)ͽI՝䁽ѠܸԔѥ͕́ɕѕ+qͽѥϊtqѕtȃqٕ䁽ѕtɝѥѼхѡ)ѥ́ѡЁѠɽѥѥѕ)ɵеٕɕɕչ͕) ͥAɕ䁅ͥ́ɕٕͥѥٔɽɅ)э̰՝ѥѡЁѡ́ѕѠɽɅ́)ٕͥͽѥȁѕɅѥɵ)Ѽхɐ䁍ɔɕͥɕѥٔɅ)ѥϊd́Ѽ5Q4͕٥̸ɔɕ͕ɍ́)ѼᅵѡЁѥٕ́ѡ́Ʌѥ)ɔѥеɕѕэٕ͔́ձѥ)͕ѥ̸(ظ]Ё5́ѥٔU͕ȁ%ѕə)ȁYՅ ɔMѥ)MЁ ɽݸ-٥0MѠ9@9@9@)ḭͥ%) ɽչ%مѥٔɔٕѡɽ՝٥Յɔ)́ɵ́ѕѥȁɥ٥ɔՅ䁅)䰁ѽ饹Ёȁѥ̰ɽѥѥ)ЁѼɽՍͥѥٔѠэ̸!ݕٕȰ)ɔ٥Յɔٔ́ѕѥѥ́Ѽ)ɅиU͕ȁɥU`́ɽɥ٥)ѥхѠѕ́٥Յɔ%)аѥх͔ѕ䁅ɔѥɕд)Ѽ͔͔ѡɍٕѥ䁽مȴ)ѥ)5ѡiͥ́ѹɕݥѠ͕ȁɥ)ձѥɴѼəɴɕͥٔU`ɕ͕ɍɽи)Q́ɽЁͥѕāѕ٥́ɥݡ͕)ݽɭѡɽ՝͕ɥ́хͭ́ѡѥEՅф)ѥٔՅѥхѥٔф݅́ѕѼمՅєѡ͕)ɥѠɔѕȁɕͥ)IձQѕ٥́չٕɕ͕ٕɅхЁɕ)U`́Ѽɕ)͔͗Qѡɽ́ȁͥɔ́Ѽͥ)եѥٔȁѥ́ͥɔ)хѥϊQѥ́݅ЁѼ܁ݡЁѼЁɕɐ)ɽ̰嵕аͥэ́ɥȁѼхѥ)٥ͥи)Ʌѥɕɕ̃QɕЁɽ́ɕɕѼ)ѕɅЁݥѠ٥Յɔɕѱ䰁م她ش)́ͥхѡɽ՝Ёѡɽ̸)ѡQѥ́ݕɔ͕ѡѥՅ)хѕɅѥ̰Ё́ѡݽձͽѕɅѥ)ݥѠѡɔɽ٥ȸ) ͥAеɕͥѕ٥́єѡЁ͕ȴ)ѕɕͥ٥ՅɔɽٔѥЁͅѥ͙)ѥQɕͥљɴ́٥ѼЁ͔ݥѠ)͕ٕɅѠѕ̸ѥѕɕձ̰͕U`)ѕٕѥ́مɥ䁽ɥ́ͽ݅ɔɽՍ̰)ՑɽٕѥɕՍ٥ͥЁа(ȁA